Suppliers / CSL BEHRING

CSL BEHRING

Switzerland 2 duplicate records merged Updated 9 July 2026

CSL BEHRING is a finished-dose manufacturer based in Switzerland. It holds one valid CEP. Its filings concentrate with EMA, AIFA (IT) and Health Canada. Its GMP standing is certified by ZLG (DE), EMA and ANVISA (Brazil), among 5 authorities. Its most recent recorded inspection, by US FDA, closed on 2 March 2023 as VAI.

0
active US DMFs
1
valid CEPs
12
registered plants 2 with an FDA FEI number
1,052
filings across 32 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
4 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 2 March 2023 VAI US FDA
  • 4 March 2022 VAI US FDA
  • 24 September 2021 VAI US FDA
  • 18 February 2020 VAI US FDA
  • 23 May 2019 VAI US FDA
  • 18 October 2018 VAI US FDA
  • 13 April 2018 VAI US FDA
  • 19 July 2017 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Bern, United Arab Emirates Not on file
Bern, United Arab Emirates Not on file
35041 Marburg, United Arab Emirates Not on file
BERN (BERNA), Switzerland Not on file
Bern, Switzerland Not on file
Switzerland, Switzerland 3002806716

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Water For Injections EDQM 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA 136 6
AIFA (IT) 115 None
Health Canada 115 None
FAMHP (BE) 87 None
INFARMED (PT) 63 None
MEDSAFE (NZ) 61 None
ZLG (DE) None 8
ANVISA (Brazil) None 4
HSA (SG) None 1
EAEU_EEC None 1

Scale

Year Revenue Exports Destinations
2023 $30.0B Not reported Not reported
2022 $20.0B Not reported Not reported
2021 $20.0B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. CSL BEHRING comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 2 March 2023.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported